S&P Futures
4,145.25 +3.50 (+0.08%) Dow Futures
32,823.00 +31.00 (+0.09%) Nasdaq Futures
13,190.25 +7.00 (+0.05%) Russell 2000 Futures
1,943.80 +2.70 (+0.14%) Crude Oil
90.09 -0.67 (-0.74%) Gold
1,801.60 -3.60 (-0.20%)
Denali Therapeutics Inc. (DNLI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 35.75 |
| Open | 36.12 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 36.12 - 38.70 |
| 52 Week Range | 20.24 - 56.80 |
| Volume | |
| Avg. Volume | 640,290 |
| Market Cap | 4.58B |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.08 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DNLI
Related Research
- Denali Therapeutics Inc.Daily – Vickers Top Buyers & Sellers for 07/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat12 days agoArgus Research
- Zacks
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights. “The Phase 1 study of DNL919 (ATV:TREM2) is now underway, making this our third BBB Transport Vehicle (TV)-enabled program,
- Zacks
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
